Oseltamivir
Revision as of 22:16, 26 April 2016 by Rossdonaldson1 (talk | contribs) (Created page with "==Administration== *Type: *Dosage Forms: *Routes of Administration: *Common Trade Names: Tamiflu ==Adult Dosing== ===Influenza==== *75mg PO BID x 5 days ==Pediatric Do...")
Administration
- Type:
- Dosage Forms:
- Routes of Administration:
- Common Trade Names: Tamiflu
Adult Dosing
Influenza=
- 75mg PO BID x 5 days
Pediatric Dosing
Influenza=
- Age <1 year: 3mg/kg PO BID x 5 days
- <15kg: 30mg PO BID x 5 days
- 15-23kg: 45mg PO BID x 5 days
- 24-40kg: 60mg PO BID x5d
- Adult: 75mg PO BID x 5 days
Special Populations
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
Mechanism of Action
Comments
- Influenza
- Shortens duration of illness by 16.8 hrs while NNTH (number needed to harm) was 28 in regards to causing n/v, HA, and renal and psych syndromes[1]
- Greatest benefit if within 48hrs of symptom onset[2]
- However, may be beneficial up to 4-5 days, including in pregnant patients
- Early treatment of hospitalized pts can reduce death
See Also
References
- ↑ Jefferson T, et al. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014; 348:g2545.
- ↑ CDC Guidelines. 2015-2016. http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm